{
    "clinical_study": {
        "@rank": "132667", 
        "arm_group": [
            {
                "arm_group_label": "New formulation of adalimumab 40 mg eow", 
                "arm_group_type": "Experimental", 
                "description": "New formulation adalimumab 40 mg eow"
            }, 
            {
                "arm_group_label": "Current formulation adalimumab 40 mg eow", 
                "arm_group_type": "Active Comparator", 
                "description": "Current formulation adalimumab 40 mg eow"
            }
        ], 
        "brief_summary": {
            "textblock": "A study in Rheumatoid Arthritis (RA) patients to look at two formulations of adalimumab for\n      pharmacokinetic and safety."
        }, 
        "brief_title": "A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Adalimumab for Pharmacokinetic, Pharmacodynamic and Safety", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female subject, 18 years or older who has a diagnosis of Rheumatoid Arthritis\n             (RA) as defined by the 1987-revised American College of Rheumatology\n             (ACR)-classification criteria or the new American College of Rheumatology\n             (ACR)/European League Against Rheumatism (EULAR) diagnostic criteria for RA\n             2010-classification criteria and has a disease duration for a minimum of 3 months.\n\n          -  Subjects must be na\u00efve to biologic therapy.\n\n          -  Subject must meet the following criteria for the joint assessment: \u2022 At least 6\n             swollen joints out of 66 assessed. \u2022 At least 6 tender joints out of 68 assessed.\n\n          -  Prior Disease Modifying Antirheumatic Drug (DMARD) therapy: a) Subjects not on\n             methotrexate at baseline must remain without methotrexate throughout the study.\n             Subjects on prior Methotrexate (MTX) must have discontinued at least 28 days prior to\n             Week 0 (Day 1). b) Subjects on Disease Modifying Antirheumatic Drug (DMARD) therapy\n             other than Methotrexate (MTX) (except prednisone/prednisolone less than or equal to\n             10 mg) must discontinue it for at least 28 days before the first dose of\n             investigational product at Week 0 (Day 1).\n\n          -  Female subjects are either not of childbearing potential, defined as postmenopausal\n             for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral\n             oophorectomy and/or hysterectomy), or are practicing at least 1 of the following\n             methods of birth control throughout the study and for at least 150 days after the\n             last dose of study drug: \u2022 Condoms, sponge, foams, jellies, diaphragm or intrauterine\n             device (IUD). \u2022 Hormonal contraceptives for 90 days prior to study drug\n             administration. \u2022 Vasectomized partner(s).\n\n          -  Subjects must be able and willing to self-administer subcutaneous (SC) injections or\n             have a qualified person available to administer subcutaneous (SC) injections.\n\n          -  Subject is judged to be in good general health as determined by the Principal\n             Investigator based upon the results of medical history, physical examination,\n             laboratory profile, chest x-ray (CXR), and 12 lead electrocardiogram (ECG) performed\n             during Screening.\n\n          -  Subject has a negative Tuberculosis (TB) screening assessment (including a (Purified\n             Protein Derivative (PPD) test or QuantiFERON-Tuberculosis (TB) Gold test or\n             equivalent) and negative chest x-ray (Posterior-Anterior (PA) and lateral view) at\n             Screening.  If a subject has evidence of a latent Tuberculosis (TB) infection, the\n             subject must initiate and complete a minimum of 2 weeks of anti-Tuberculosis (TB)\n             therapy or have documented completion of a course of anti-Tuberculosis (TB) therapy\n             prior to Baseline.\n\n          -  Subjects must be willing to provide written consent and to comply with the\n             requirements of this study protocol.\n\n        Exclusion Criteria:\n\n          -  Subject has been treated with intra-articular or parenteral administration of\n             corticosteroids in the preceding 4 weeks from Baseline visit.  Inhaled\n             corticosteroids for stable medical conditions are allowed.  Oral of less than or\n             equal to 10 mg/d prednisone equivalent are allowed.\n\n          -  Subject has been treated with any investigational drug of a chemical or biological\n             nature within a minimum of 30 days or 5 half-lives (whichever is longer) of the drug\n             prior to Baseline Visit.\n\n          -  Subject has a history of acute inflammatory joint disease of different origin other\n             than Rheumatoid Arthritis (RA) (e.g., seronegative spondyloarthropathy, psoriatic\n             arthritis, Reiter's syndrome, systemic lupus erythematosus, gouty arthritis, or any\n             arthritis with onset prior to age 17 years).\n\n          -  Known hypersensitivity to adalimumab or its excipients.\n\n          -  Subject currently uses or plans to use anti-retroviral therapy at any time during the\n             study.\n\n          -  History of demyelinating disease (including myelitis) or neurologic symptoms\n             suggestive of demyelinating disease.\n\n          -  History of invasive infection (e.g., listeriosis and histoplasmosis), human\n             immunodeficiency syndrome (HIV).\n\n          -  Chronic recurring infections or active Tuberculosis (TB).\n\n          -  History of moderate to severe congestive heart failure (New York Heart Association\n             (NYHA) class III or IV), recent cerebrovascular accident and any other condition\n             which, in the opinion of the investigator, would put the subject at risk by\n             participation in the protocol.\n\n          -  Evidence of dysplasia or history of malignancy (including lymphoma and leukemia)\n             other than a successfully treated non-metastatic cutaneous squamous cell or basal\n             cell carcinoma or localized carcinoma in situ of the cervix.\n\n          -  Subject received any live vaccine within 3 months prior to study drug administration.\n               - Subject has a history of clinically significant hematologic (e.g., severe anemia,\n             leukopenia, thrombocytopenia), renal or liver disease (e.g., fibrosis, cirrhosis,\n             hepatitis).\n\n          -  Positive pregnancy test at Screening or Baseline.\n\n          -  Subject is considered by the investigator, for any reason, to be unsuitable candidate\n             for the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01712178", 
            "org_study_id": "M13-390", 
            "secondary_id": "2012-000535-36"
        }, 
        "intervention": [
            {
                "arm_group_label": "Current formulation adalimumab 40 mg eow", 
                "description": "Current formulation adalimumab 40 mg eow", 
                "intervention_name": "Adalimumab, current formulation", 
                "intervention_type": "Biological", 
                "other_name": "Humira"
            }, 
            {
                "arm_group_label": "New formulation of adalimumab 40 mg eow", 
                "description": "New Formulation 40 mg eow", 
                "intervention_name": "Adalimumab, new formulation", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Adalimumab"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Pharmacodynamic,Pharmacokinetic", 
        "lastchanged_date": "June 3, 2013", 
        "link": {
            "description": "This clinical study may be evaluating a usage that is not currently FDA-approved. Please see US prescribing information for approved uses.", 
            "url": "http://rxabbvie.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Paradise Valley", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85253"
                    }, 
                    "name": "Site Reference ID/Investigator# 75073"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hemet", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92543"
                    }, 
                    "name": "Site Reference ID/Investigator# 75077"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wichita", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "67203"
                    }, 
                    "name": "Site Reference ID/Investigator# 75076"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Clifton", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07012"
                    }, 
                    "name": "Site Reference ID/Investigator# 75075"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19152"
                    }, 
                    "name": "Site Reference ID/Investigator# 83133"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charleston", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29406"
                    }, 
                    "name": "Site Reference ID/Investigator# 75074"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brussels", 
                        "country": "Belgium", 
                        "zip": "1200"
                    }, 
                    "name": "Site Reference ID/Investigator# 75100"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Liege", 
                        "country": "Belgium", 
                        "zip": "4000"
                    }, 
                    "name": "Site Reference ID/Investigator# 75101"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brno", 
                        "country": "Czech Republic", 
                        "zip": "63800"
                    }, 
                    "name": "Site Reference ID/Investigator# 75104"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Prague 2", 
                        "country": "Czech Republic", 
                        "zip": "128 50"
                    }, 
                    "name": "Site Reference ID/Investigator# 76788"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Uherske Hradiste", 
                        "country": "Czech Republic", 
                        "zip": "686 01"
                    }, 
                    "name": "Site Reference ID/Investigator# 75102"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zlin", 
                        "country": "Czech Republic", 
                        "zip": "760 01"
                    }, 
                    "name": "Site Reference ID/Investigator# 75103"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ratingen", 
                        "country": "Germany", 
                        "zip": "40882"
                    }, 
                    "name": "Site Reference ID/Investigator# 78014"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Caguas", 
                        "country": "Puerto Rico", 
                        "zip": "00725"
                    }, 
                    "name": "Site Reference ID/Investigator# 75079"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vega Baja", 
                        "country": "Puerto Rico", 
                        "zip": "00694-0764"
                    }, 
                    "name": "Site Reference ID/Investigator# 75078"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bucharest", 
                        "country": "Romania", 
                        "zip": "020475"
                    }, 
                    "name": "Site Reference ID/Investigator# 76787"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cluj-Napoca", 
                        "country": "Romania", 
                        "zip": "400006"
                    }, 
                    "name": "Site Reference ID/Investigator# 75978"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ploiesti", 
                        "country": "Romania", 
                        "zip": "100337"
                    }, 
                    "name": "Site Reference ID/Investigator# 76433"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Banska Bystrica", 
                        "country": "Slovakia", 
                        "zip": "97405"
                    }, 
                    "name": "Site Reference ID/Investigator# 76934"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Senica", 
                        "country": "Slovakia", 
                        "zip": "905 01"
                    }, 
                    "name": "Site Reference ID/Investigator# 76935"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zilina", 
                        "country": "Slovakia", 
                        "zip": "010 01"
                    }, 
                    "name": "Site Reference ID/Investigator# 76682"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Belgium", 
                "Czech Republic", 
                "Germany", 
                "Puerto Rico", 
                "Romania", 
                "Slovakia"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Study to Assess the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of a New Adalimumab Formulation in Subjects With Active Rheumatoid Arthritis", 
        "overall_official": {
            "affiliation": "AbbVie", 
            "last_name": "Udayasankar  Arulmani, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Belgium: Federal Agency for Medicinal Products and Health Products", 
                "Czech Republic: State Institute for Drug Control", 
                "Germany: Paul-Ehrlich-Institut", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
                "Romania: National Medicines Agency", 
                "Slovakia: State Institute for Drug Control"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Measures the amount of drug in the body", 
                "measure": "Change from baseline in study drug concentration in the blood", 
                "safety_issue": "No", 
                "time_frame": "Measured at Weeks 0, 4, 8, 10, 10+3 days, 11, 11+3 days, 12, 16, 20, and 24"
            }, 
            {
                "description": "Measures rheumatoid arthritis activity by C-reactive protein laboratory value (measures inflammation in the body) and tender and swollen joints", 
                "measure": "Change in Disease Activity Score (DAS28)", 
                "safety_issue": "No", 
                "time_frame": "Measured up through Week 24"
            }, 
            {
                "description": "Percentage of subjects who respond to treatment", 
                "measure": "American College of Rheumatology (ACR) 20/50 Responder Rates", 
                "safety_issue": "No", 
                "time_frame": "Measured through Week 24"
            }, 
            {
                "description": "Subject Questionnaire measuring how rheumatoid arthritis affects functioning in daily life", 
                "measure": "Physical function  assessed by the Health Assessment Questionnaire (HAQ-DI)", 
                "safety_issue": "No", 
                "time_frame": "Measured through Week 24"
            }, 
            {
                "description": "Subject questionnaire measuring quality of life", 
                "measure": "Health survey assessment using the Short Form-36 (SF-36)", 
                "safety_issue": "No", 
                "time_frame": "Measured through Week 24"
            }, 
            {
                "description": "Percentage of subjects with anti-adalimumab antibody", 
                "measure": "Anti-adalimumab Antibody", 
                "safety_issue": "Yes", 
                "time_frame": "Measured through Week 24"
            }, 
            {
                "description": "Number of participants with adverse events", 
                "measure": "Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 70 days following last dose of study drug"
            }, 
            {
                "description": "Subject's injection pain is measured using a Visual Analog Scale (VAS)", 
                "measure": "Patient's Assessment of Injection Site Related Pain", 
                "safety_issue": "Yes", 
                "time_frame": "Immediately after injections on Day 1"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01712178"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "AbbVie", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AbbVie (prior sponsor, Abbott)", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}